Get the Stockscreener App
19.96
5.94%
1.12
After Hours:
20.04
0.08
+0.40%
Avalo Therapeutics Inc stock is traded at $19.96, with a volume of 1.61M.
It is up +5.94% in the last 24 hours and up +52.37% over the past month.
Avalo Therapeutics Inc is a clinical stage biotechnology company fully dedicated to developing IL-1B-based treatments for immune-mediated inflammatory diseases. The company's asset is Abdakibart (AVTX-009) an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalos pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein), AVTX-006 and AVTX-913.
See More
Previous Close:
$18.84
Open:
$19.2
24h Volume:
1.61M
Relative Volume:
0.87
Market Cap:
$1.05B
Revenue:
$59,000
Net Income/Loss:
$-84.74M
P/E Ratio:
-3.4283
EPS:
-5.8222
Net Cash Flow:
$-59.69M
1W Performance:
+3.47%
1M Performance:
+52.37%
6M Performance:
+25.50%
1Y Performance:
+302.42%
1-Day Range:
$19.12
$20.35
1-Week Range:
$17.23
$20.35
52-Week Range:
$4.61
$24.27
Avalo Therapeutics Inc Stock (AVTX) Company Profile
Name
Avalo Therapeutics Inc
Sector
Industry
Phone
410-522-8707
Address
1500 LIBERTY RIDGE DRIVE, WAYNE
Compare AVTX vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AVTX
Avalo Therapeutics Inc
|
19.96 | 971.41M | 59,000 | -84.74M | -59.69M | -5.8222 |
VRTX
Vertex Pharmaceuticals Inc
|
529.59 | 126.07B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
649.81 | 65.37B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
916.80 | 57.70B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
313.04 | 40.19B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
189.99 | 39.82B | 742.00K | -1.37B | -1.07B | -7.0731 |
Avalo Therapeutics Inc Stock (AVTX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-09-26 | Initiated | Wolfe Research | Outperform |
| Apr-06-26 | Initiated | Citizens | Mkt Outperform |
| Feb-02-26 | Initiated | Guggenheim | Buy |
| Dec-18-25 | Initiated | Mizuho | Outperform |
| Sep-17-25 | Reiterated | H.C. Wainwright | Buy |
| Sep-05-25 | Initiated | TD Cowen | Buy |
| Aug-15-25 | Initiated | Cantor Fitzgerald | Overweight |
| Jun-02-25 | Resumed | H.C. Wainwright | Buy |
| Mar-25-25 | Initiated | Jefferies | Buy |
| Mar-25-25 | Initiated | Stifel | Buy |
| Feb-28-25 | Initiated | Piper Sandler | Overweight |
| Feb-21-25 | Initiated | Wedbush | Outperform |
| Dec-19-24 | Initiated | BTIG Research | Buy |
| Oct-24-24 | Initiated | H.C. Wainwright | Neutral |
| Apr-16-24 | Upgrade | Oppenheimer | Perform → Outperform |
| Sep-24-21 | Initiated | RBC Capital Mkts | Outperform |
View All
Avalo Therapeutics Inc Stock (AVTX) Latest News
AVTXAvalo Therapeutics Inc Latest SEC Filings - Finviz
Why Did AVTX Stock Surge 45% In Pre-Market Today? - Stocktwits
Price to earnings forward of Avalo Therapeutics, Inc. – NASDAQ:AVTX - TradingView
Enterprise value to revenue forward of Avalo Therapeutics, Inc. – NASDAQ:AVTX - TradingView
Price to sales forward of Avalo Therapeutics, Inc. – NASDAQ:AVTX - TradingView
Price to book forward of Avalo Therapeutics, Inc. – NASDAQ:AVTX - TradingView
Price to sales forward of Avalo Therapeutics Inc – LSX:A3E2FR - TradingView
Avalo Therapeutics (AVTX) Is Up 12.9% After Broad Russell Index AdditionsWhat's Changed - Yahoo Finance
Avalo Therapeutics Inc Actuals & Estimates (NASDAQ:AVTX) - TradingView
Avalo Therapeutics, Inc.(NasdaqCM:AVTX) added to Russell Small Cap Comp Growth Benchmark - marketscreener.com
Avalo Therapeutics, Inc.(NasdaqCM: AVTX) added to Russell 2500 Growth Benchmark - marketscreener.com
Avalo Therapeutics, Inc.(NasdaqCM: AVTX) added to Russell 2000 Index - marketscreener.com
Avalo Therapeutics, Inc.(NasdaqCM: AVTX) added to Russell 2000 Value Benchmark - marketscreener.com
Avalo Therapeutics, Inc.(NasdaqCM: AVTX) added to Russell 2000 Growth Benchmark - marketscreener.com
Avalo Therapeutics, Inc.(NasdaqCM: AVTX) added to Russell 3000E Growth Benchmark - marketscreener.com
Avalo Therapeutics (AVTX) Joins Russell 2000 and 3000 Indices - GuruFocus
Avalo Therapeutics added to Russell 2000 and 3000 indexes By Investing.com - Investing.com Australia
Avalo Therapeutics added to Russell 2000 and 3000 indexes - Investing.com
Avalo Therapeutics to Join Russell 2000, Russell 3000 Indexes - marketscreener.com
Avalo Therapeutics to Join the Russell 2000® and Russell 3000® Indexes - GlobeNewswire
AVTX Forecast — Price Target — Prediction for 2027 - TradingView
Avalo Therapeutics CMO Mittie Doyle sells $26,100 of shares - Investing.com UK
Avalo Therapeutics CMO Mittie Doyle sells $26,100 of shares By Investing.com - Investing.com Australia
Avalo Therapeutics Inc Actuals & Estimates (FWB:C6K0) - TradingView
Form 4 Avalo Therapeutics Inc For: 25 June By Investing.com - Investing.com Australia
Avalo Therapeutics (AVTX) CMO trades 1,450 shares in 10b5-1 exercise-and-sell - Stock Titan
Avalo Therapeutics (AVTX) director awarded 40,200 stock options at $17.83 strike - Stock Titan
[Form 3] Avalo Therapeutics, Inc. Initial Statement of Beneficial Ownership - Stock Titan
Avalo Therapeutics Inc (AVTX) Valuation: PE, PB & Fair Value Analysis - TradingKey
Form 8K Avalo Therapeutics Inc For: 23 June By Investing.com - Investing.com Nigeria
Why Avalo Therapeutics, Inc. (AVTX) Is Among the Best Low Priced Stocks to Get Rich in 2026 - Insider Monkey
Avalo Therapeutics appoints Ron Philip to board of directors By Investing.com - Investing.com India
Avalo Therapeutics appoints Ron Philip to board of directors - Investing.com
Avalo Therapeutics Appoints Ron Philip to Board of Directors - The Manila Times
Avalo appoints Ron Philip to Board, joins Compensation and Science committees - TradingView
Ron Philip joins Avalo Therapeutics (AVTX) board with stock option grant - Stock Titan
5 Best Low Priced Stocks to Get Rich in 2026 - Insider Monkey
Avalo Therapeutics Inc (AVTX) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Avalo Therapeutics, Inc.(NasdaqCM:AVTX) added to S&P Biotechnology Select Industry Index - marketscreener.com
AVALO THERAPEUTICS INC (AVTX) Stock Chart - ChartMill
Commodore Capital (AVTX) reports 5.72M-share, 9.9% position in Avalo - Stock Titan
Avalo Therapeutics Inc (AVTX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Avalo Therapeutics Inc (AVTX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Avalo Therapeutics Inc (AVTX) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Avalo Therapeutics Inc (AVTX) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Avalo Therapeutics Inc (AVTX) Institutional Confidence - TradingKey
Avalo Therapeutics Inc Stock (AVTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Avalo Therapeutics Inc Stock (AVTX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Doyle Mittie | Chief Medical Officer |
Jun 23 '26 |
Sale |
18.00 |
1,450 |
26,100 |
51,776 |
0.05%
0.74%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):